Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed
to estimate the association of treatment success and death with the use of individual drugs, …

Background Chronic respiratory disease causes substantial global morbidity and mortality.
The contribution of pulmonary tuberculosis to the aetiology of chronic respiratory disease is …

Background. The treatment of extensively drug-resistant tuberculosis (XDR TB) presents a
major challenge. Second-line antimycobacterial drugs are less effective, more toxic, and more …

The production of guidelines for the management of drug-resistant tuberculosis (TB) fits the
mandate of the World Health Organization (WHO) to support countries in the reinforcement of …

Background Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic,
expensive, and has generally poor outcomes. We undertook an individual patient data meta-…

Background Despite the prevalence of multidrug-resistant tuberculosis in nearly all low-income
countries surveyed, effective therapy has been deemed too expensive and considered …

Background Extensively drug-resistant tuberculosis has been reported in 45 countries,
including countries with limited resources and a high burden of tuberculosis. We describe the …

… In 2018, WHO updated the IPDMA with additional data and recommended delamanid be
included in the third tier of drugs, Group C, and for the drug to be used in the treatment of …

SETTING: Globally it is estimated that 273000 new cases of multidrug-resistant tuberculosis
(MDR-TB, resistance to isoniazid and rifampicin) occurred in 2000. To address MDR-TB …

A comment on this article appears in" DOTS plus strategy in resource-poor countries." Int J
Tuberc Lung Dis. 1999 Sep; 3 (9): 843; author reply 844. A comment on this article appears in…